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Background. Innate and adaptive immune responses
are pivotal in atherosclerosis, but their association
with early-stage atherosclerosis in humans is
incompletely understood. In this regard, untreated
children with familial hypercholesterolaemia may
serve as a human model to investigate the effect of
elevated low-density lipoprotein (LDL)-cholesterol.
Objectives. We aimed to study the immunological and
inflammatory pathways involved in early
atherosclerosis by examining mRNA molecules in
peripheral blood mononuclear cells (PBMCs) from
children with FH.
Methods. We analysed the level of 587 immune-
related mRNA molecules using state-of-the-art
Nanostring technology in PBMCs from children
with (n = 30) and without (n = 21) FH, and from FH
children before and after statin therapy (n = 10).
Results. 176 genes (30%) were differentially
expressed between the FH and healthy children
at P < 0.05. Compared to healthy children, the
dysregulated pathways in FH children included
the following: T cells (18/19); B cells (5/6);
tumour necrosis factor super family (TNFSF) (6/
8); cell growth, proliferation and differentiation
(5/7); interleukins (5/9); toll-like receptors (2/5);
apoptosis (3/7) and antigen presentation (1/7),
where the ratio denotes higher expressed genes to
total number of genes. Statin therapy reversed
expression of thirteen of these mRNAs in FH
children.
Conclusion. FH children display higher PBMC expres-
sion of immune-related genes mapped to several
pathways, including T and B cells, and TNFSF than
healthy children. Our results suggest that LDL-C
plays an important role in modulating expression
of different immune-related genes, and novel data
on the involvement of these pathways in the early
atherosclerosis may represent future therapeutic
targets for prevention of atherosclerotic progres-
sion.
Keywords: familial hypercholesterolaemia, children,
gene expression, inflammation, statins.
Introduction
Coronary heart disease (CHD) is a main contrib-
utor to the global burden of disease [1]. It is
primarily caused by atherosclerosis where a
complex interaction between lipids and inflamma-
tion is the pathological hallmark [2]. Innate
immune responses are pivotal through for exam-
ple the formation of foam cells from lipid-exposed
macrophages, which in turn activate cells in the
adaptive immune system, such as T and B cells.
These cells may again activate innate immunity†Contributed equally.
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through for example release of various inflamma-
tory cytokines. All these subsets are important cell
types in atherosclerosis [2]. Peripheral blood
mononuclear cells (PBMCs), which comprise lym-
phocytes and monocytes, may thus be considered
a unique niche since they are primed by athero-
genic factors and directly contribute to the
atherosclerosis process. Furthermore, previous
studies have shown that alterations in PBMC gene
expression level may reflect systemic health [3]
and have suggested PBMCs to be a good model
system to elucidate the cardiovascular system in
relation to inflammation [4].
Due to the nature of CHD, most studies on
inflammation and immunity in atherosclerosis are
performed in adult patients with established
atherosclerosis [5–7]. However, these studies may
be confounded by co-occurring disease or risk
factors, or environmental exposures. Thus, find-
ings in these studies may reflect secondary phe-
nomena and not the molecules that promote the
development of atherosclerosis and its complica-
tions. It is therefore of major interest for future
prevention of CHD to identify and map molecules
that could play a pathogenic role in the early stages
of this disorder, using study populations free from
severe confounding. To this, subjects with familial
hypercholesterolaemia (FH) may represent an opti-
mal population.
FH is an inherited disorder caused primarily by a
mutation in the gene encoding the low-density
lipoprotein (LDL) receptor [8]. Phenotypically, FH
individuals have higher total- and LDL-cholesterol
(LDL-C) compared to the general population, lead-
ing to accelerated atherosclerosis and premature
CHD [9]. Accordingly, nonstatin-treated children
with FH may serve as a human model to investi-
gate the isolated effect of LDL-C on early develop-
ment of atherosclerosis caused by a mutation
rather than secondary hypercholesterolaemia
induced by, for example lifestyle. Indeed, it has
been shown that FH children have increased
carotid intima–media thickness (IMT) [10] and
display signs of inflammation [11] at both protein
and mRNA level, including activation of certain
pathways such as members of the tumour necro-
sis factor super family (TNFSF) [10, 12]. However,
these issues are far from clear and to this end; to
the best of our knowledge, no studies have shown
comprehensive mapping of the multitude of
inflammatory and immune-related pathways that
could be involved in the early stages of atheroscle-
rosis in children with FH.
Herein, we aimed to profile the immunological and
inflammatory pathways involved in early
atherosclerosis in PBMCs from children with FH
compared to healthy children.
Methods
Subjects
The subjects have been described previously [12].
Briefly, children with FH were recruited from the
Lipid Clinic, Oslo University Hospital, Norway. Age-
and sex-matched (by median and ranges) healthy
control children were recruited through colleagues,
employees and friends at the Lipid Clinic and the
Department of Nutrition, University of Oslo, Nor-
way. Common inclusion criterion for the two
groups was age 18 years or younger. Common
exclusion criteria for the two groups were any
chronic disease (including inflammatory or meta-
bolic disorders), or use of anti-inflammatory drugs
or lipid-lowering therapy (LLT) (at first visit). A
nonfasting blood sample was obtained from each
individual. Additionally, nonfasting blood samples
were available before and after statin treatment in
ten FH children, also previously described [12]. The
study was approved by the Regional Committee of
Medical Ethics and was conducted according to the
Declaration of Helsinki. Written informed consent
was obtained from all participants, or from one of
their parents if the child was below the age of
16 years.
Gene expression analyses
PBMCs were isolated, and RNA quantity and qual-
ity were analysed as previously described [12]. We
ran RNA expression analysis on the nCounter 
analysis system (Nanostring Technologies), run-
ning 12 samples at a time (one ‘strip’). The proce-
dure was performed according to the
manufacturer´s instructions, applying about
100 ng mRNA. The kit used was a fixed code set
for mRNA analysis that comprised genes involved
in human immunology: nCounter GX Human
Immunology Kit v2 (Nanostring Technologies).
The number of mRNA molecules per gene was
accounted for detection level average
ðnegativecontrolÞ þ 2SDðnegativecontro lsÞ= 10
mRNA molecules, normalized against instrument
variations (positive controls) and endogenous con-
trol genes found to be stable (ABCF1, EEF1G,
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HPRT1, RPL19, TUBB, GUSB and POLR2A) using
nSolver analysis software 2.5.34 (NanoString Tech-
nologies).
Miscellaneous
Oxidized LDL (oxLDL) was measured in serum
using an enzyme-linked immunosorbent assay as
previously described [12]. Standard blood bio-
chemistry analyses were measured in plasma or
serum by standard methods at the accredited
medical laboratory, Oslo University Hospital, Rik-
shospitalet, Oslo, Norway (NS-EN ISO
15189:2007). Not all analyses were performed in
all subjects because of the limited volume of blood
sample available from each individual.
Statistical analyses
We imported the raw gene expression data (594
genes) into Partek Genomics Suite 6.6, and batch-
corrected for strip, age and sex. In principal
component analysis (PCA), one individual was a
clear outlier and was thus excluded from the
statistical analyses. Statistical power analysis
based on the entire dataset showed that the
minimum sample size for this study was 17 at
significance level 0.01 and power 0.90. After
exclusion of the used endogenous controls (n = 7,
see gene expression analysis section), we per-
formed a 4-way analysis of variance (ANOVA) model
using log2-transformed data to test for statistical
significance between FH children and healthy
children and adjusted for multiple testing using
false discovery rate (FDR). FDR-adjusted P-
value < 0.05 was considered significantly different
between the groups. Additionally, based on data
from the 4-way ANOVA as input, we ran standard
linear regression models for each gene using batch-
corrected raw data in R version 3.5.0 [13]. We ran
three models per gene, with 1) no covariates, 2)
HDL-C and CRP as covariates, or 3) LDL-C as
covariate. Also, to further examine associations
between gene expression and clinical and biochem-
ical variables, we used Spearman’s rank correla-
tion.
For the main cohort, we allocated differentially
expressed genes (DEGs) into different immunolog-
ical pathways using two strategies. First, we man-
ually allocated FDR-adjusted genes to pathways
based on their function; main pathways were
defined as having ≥ 5 DEGs. Information about
gene function was obtained from the following
databases NCBI (https://www.ncbi.nlm.nih.gov/
pubmed/, main resource), STRING (https://
string-db.org), GeneCards (https://www.genecard
s.org), UniProt (https://www.uniprot.org), OMIM
(http://omim.org/) and Ensembl (http://www.e
nsembl.org/). Secondly, we created clusters of
genes (not FDR-adjusted) in an unsupervised
manner; we calculated the Euclidean distance of
the correlation matrix for all genes, performed
hierarchical clustering (complete linkage) and cut
the dendrogram into eight clusters.
We estimated the relative proportion of blood cell
types in each sample with the CIBERSORT algo-
rithm [14]. The algorithm takes a whole-genome
gene expression matrix as input and returns the
relative proportion of 22 leucocyte subtypes by use
of feature selection and linear support vector
regression (SVR). Because we supplied the algo-
rithm with a limited number of genes (n = 587), the
sensitivity of this analysis was expected to be lower
than by use of whole-genome datasets. Despite
this, all 51 samples had adequate goodness of fit
(P < 0.05). Since the PBMC pool should be com-
pletely absent neutrophils, we used the estimated
proportion of neutrophils as an indicator to remove
low-proportion leucocyte variables; hence, we
included mainly estimated monocyte and lympho-
cyte subtypes.
In a subsequent analysis in ten FH children that
were not part of the main FH cohort, we analysed
gene expression before and after starting statin
treatment. The analysis pipeline (gene expression
and statistical analyses) was similar as for the
main cohort, described above. As for the main
cohort, we estimated the change in gene expression
(for all genes) corrected for age, sex and strip upon
statin therapy. Then, we investigated the associa-
tion between the two sets of coefficient estimates
(for each of the 587 genes): (i) the association
between FH and healthy children (exposure vari-
able) and (ii) the change upon statin therapy
(outcome variable). We interpreted this association
as whether or not statins completely or partially
reversed the gene expression differences observed
in FH children compared to control children.
Baseline characteristics are given as median
(25th75th percentile), mean (standard deviation
[SD]) or frequency (%). Mann–Whitney U test or
Independent sample t-test was used to test for
statistically significant differences in baseline
characteristics between the two groups. We used
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The characteristics of the participants are shown in
Table 1. Thirty children with and twenty-one with-
out FH were included in this substudy. All the
children with FH had a genetically verified FH
diagnosis. Total cholesterol, LDL-C, apolipoprotein
(apo) B, oxLDL and C-reactive protein (CRP) were
higher (P < 0.001), whereas high-density lipopro-
tein cholesterol (HDL-C) was lower (nonsignificant,
P = 0.059), in the FH children compared to control
children.
DEGs between FH and healthy children
Of the 587 examined genes, 176 were differentially
expressed between the FH and healthy children
after adjustment for strip, age and sex at P < 0.05
(unadjusted, Fig. 1a). The most DEGs sorted by
significance level are shown in Fig. 1b. After
adjustment for 5 % FDR, ninety-three genes were
differentially expressed between FH and healthy
children, and these were allocated into 21 related
pathways. In FH versus healthy children, the main
pathways (defined as ≥ 5 allocated genes) related
to these genes were T cells (18/19); B cells (5/6);
TNFSF (6/8); cell growth, proliferation and differ-
entiation (5/7); interleukins (5/9); toll-like
receptors (TLR) (2/5); apoptosis (3/7); antigen
presentation (1/7), where the ratio denotes higher
expressed genes to total DEGs (Fig. 2).
In order to explore the leucocyte distribution, we
predicted the different leucocyte subtypes using a
CIBERSORT analysis based on all the mRNA
expressions from the nCounter analysis. Children
with FH had higher levels of predicted na€ıve B cells
(P < 0.01), but lower levels of predicted monocytes
(P < 0.05) and resting mast cells (P < 0.01) com-
pared to healthy children (Fig. S1).
Regulation of immune-related genes after statin therapy
In order to investigate the effect of statin therapy on
immune-related genes, we analysed PBMC gene
expression before and after statin therapy in ten
children with FH. The decrease in total- and LDL-C
were 38.5 (34.5–41.4) % and 46.3 (40.6–48.9) %
(P < 0.001 for both), median (25th-75th percentile),
respectively [12]. In total, 62 genes (FDR < 0.05)
were modified by statin therapy (Fig. S2). Figure 3
shows the relationship between differences in gene
expression in FH compared to control children and
change after statin therapy in FH children. Of the
sixty-two genes, ten genes that were higher in FH
vs controls at baseline, were reduced after statin
initiation IRAK4, ATG16L1, CUL9, IKBKB, CRADD,
TRAF5, ENTPD1, C1R, IL1RL1 and CTLA4 (Fig. 3).
In contrast, CTSS, PYCARD and C14orf166 were
lower in FH vs controls at baseline and increased
Table 1. Characteristics of the participants
n FH children n Control children P *
Age, year 30 12 (11–14) 21 14 (11–14) 0.23
Sex, female 30 12 (40) 21 9 (43) 0.83
Triglycerides, mmol L1 25 0.7 (0.6–0.9) 16 0.6 (0.5–1.2) 0.75
Total-C, mmol L1 30 6.9 (6.5–7.7) 21 4.4 (4–4.7) <0.001
HDL-C, mmol L1 30 1.4 (1.2–1.5) 21 1.5 (1.3–1.7) 0.059
LDL-C, mmol L1 30 5 (4.4–5.4) 21 2.4 (2.2–2.8) <0.001
ApoA1, g L1 28 1.4 (1.3–1.5) 21 1.4 (1.4–1.6) 0.28
ApoB, g L1 29 1.2 (1.1–1.4) 21 0.6 (0.5–0.8) <0.001
oxLDL, U L1 25 105.5 (81.5–142.1) 16 53.8 (42.2–56.4) <0.001
CRP, mg L1 28 1.0 (1.0–1.0) 21 0.6 (0.6–1.0) <0.001
Glucose, mmol L1 29 4.7 (0.4) 19 4.7 (0.7) 1.00
Data are given as median (IQR), mean (SD) or frequency (%). Bold and italic P-values indicate significance and borderline
significance, respectively.
Apo, apolipoprotein; CRP, C-reactive protein; FH, familial hypercholesterolaemia; g/L, grams per litre; HDL, high-density
lipoprotein; LDL, low-density lipoprotein; mmol/L, millimoles per litre; oxLDL, oxidized low-density lipoprotein.
*Mann–Whitney U test or Independent sample t-test between the groups.
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after statin therapy (Fig. 3). Overall, statins thus
seem to partially reverse the DEGs observed in FH
children in line with the expression observed in
healthy children.
Associations between gene expression and clinical data
To further investigate associations between DEGs
in the main pathways and clinical data, we calcu-
lated the inter-variable correlation coefficients
(Fig. 4). The apoB-containing lipoprotein parame-
ters and CRP were mainly correlated to the
immune-related gene expressions. Whereas we
found mostly positive correlations between total
cholesterol, LDL-C, oxLDL, apoB and CRP, and
DEGs related to the pathways: T-cell signalling, B-
cell signalling, TNFSF signalling, and cell growth,
proliferation and differentiation (Fig. 4), the DEGs
related to antigen presentation, apoptosis and TLR
pathways were mostly negatively correlated to
apoB-containing lipoprotein parameters and CRP
(Fig. 4). There were only few correlations between
the DEGs and age, HDL-C, apoA1, triglycerides
and glucose (Fig. 4).
In addition to LDL-C, CRP and HDL-C were differ-
ent between the two groups of children (Table 1),
thus to investigate the impact of these biochemical
variables, we performed a linear regression adjust-
ing for either HDL-C and CRP combined, or LDL-C
alone, for all DEGs (n = 176) (Fig. S3). The signif-
icance of the DEGs was attenuated or neutralized
only when adjusting for LDL-C, but not when
adjusting for HDL-C and CRP, suggesting that
LDL-C is the main driver for the observed alter-
ations (Fig. S3).
In order to show a direct correlation between LDL-
C and mRNA levels, we show a strong correlation in
mRNA levels when correlating the difference per
mmol/L difference in LDL-C and difference in FH
children compared to healthy children (Fig. 5).
Discussion
In the present study, we found that FH children
display several changes in mRNA molecules related
to pathways including, for example T- and B-cell
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Fig. 1 Differentially expressed genes in PBMCs from FH children (n = 30) compared with healthy children (n = 21). (a)
Association between fold difference and nominal P-value for all genes. (b) Top 20 genes with lowest nominal P-value, here
sorted by fold difference. This analysis is based on a 4-way ANOVA using log2-transformed data as input, with strip, age and
sex as factors. Positive fold differences translate to higher expression in FH children, compared with healthy children, and
opposite for negative fold differences. Note that results are presented on log scale. ANOVA, analysis of variance; FH, familial
hypercholesterolaemia. Abbreviations of gene names are found in supplemental material.
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growth, proliferation and differentiation, compared
to healthy control children. Interestingly, the DEGs
reflected both anti-inflammatory (e.g. transforming
growth factor-b-related molecules) and pro-
inflammatory (e.g. TNFSF and various chemokines)
molecules. Furthermore, LDL-C, as expected,
seems to be the main driver of these alterations



































































































































Beta estimates (95 % CI)
P value < 0.001 < 0.01 < 0.05 ≥ 0.05
Fig. 2 Differentially expressed genes at FDR < 0.05 between FH and healthy children. Data are based on a linear
regression with input from a 4-way ANOVA using log2-transformed data as input, with strip, age and sex as factors. The x-
axis shows the beta-estimate and 95% confidence interval. ANOVA, analysis of variance; CI, confidence interval; FDR, false
discovery rate; FH, familial hypercholesterolaemia; IFN, interferon; IL, interleukin; NF-jB, nuclear factor j beta; NK, natural
killer; TLR, toll-like receptor; TNFSF, tumour necrosis factor super family. Abbreviations of gene names are found in
supplemental material.
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of inflammation also in the early stage of
atherosclerosis, before any overt disease.
Human atherosclerotic plaques contain many
immune cells, such as monocytes/macrophages,
antigen-presenting cells, and T and B lymphocytes,
of which monocytes and macrophages are the most
common cell type [15]. Recently we showed that
children with FH were characterized by monocyto-
sis with a shift towards more circulating pro-
inflammatory/nonclassical monocytes when com-
pared to healthy controls, supporting a central role
of monocytes/macrophages in early atherosclero-
sis [11]. Furthermore, in the same study, we found
a tendency to difference in distribution of certain T-
cell subsets [11]. Herein we further extend this
finding by showing an upregulation of genes
related to T- and B-cell signalling in PBMCs from
children with FH compared to control children,
suggesting an involvement of these cells in an early
stage of atherogenesis. Moreover, whereas mRNA
molecules related to antigen presentation, apopto-
sis and TLR pathway were mostly negatively cor-
related with lipid parameters and CRP, an opposite
pattern was seen for genes related to T- and B-cell
signalling suggesting that these pathways are
differently related to lipid parameters and systemic
inflammation.
Several genes related to T-cell activation (e.g.
CTLA4, CD28) and T- and B-cell interaction (ICOS)
were differently regulated in FH versus healthy
control children. Members of the B7-CD28 super-
family exert immune-regulatory effects [16]. First,
activation, expansion, differentiation and survival
of T cells are precisely regulated through co-stim-
ulatory and co-inhibitory signals after CD80/CD86
binding to CD28 and CTLA4, respectively [17]. In
experimental studies, hypercholesterolaemia has
been associated with CD28 expression on T cells in
the atherosclerotic plaque [18, 19], and blocking of
CTLA4 has been shown to prevent intimal
r = –0.38 (P = 3.9e-22)
Intercept = –0.079 (0.0073)
Slope = –0.23 (0.028)
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Fig. 3 Association between difference in PBMC gene expression in FH children (n = 30) compared with healthy children
(n = 21) and change in PBMC gene expression in the same genes upon statin treatment in FH children (n = 10).
Interpretation: each grey or orange point represents a combination of two linear regression estimates; the lower right grey-
shaded area covers genes that were higher expressed in FH children compared with healthy children, but were reduced
upon statin treatment; the upper left grey-shaded area covers genes that were lower in FH children compared with healthy
children, but were increased upon statin treatment; orange-coloured points are significant at P < 0.05 in both settings (with
95% confidence intervals). The correlation coefficient is Spearman’s rho. The intercept is where the regression line crosses x,
and the slope is the beta-coefficient. R2 is explained variance for this association. Note that the children subjected to statin
treatment (y-axis) were not the same as in the cross-sectional analysis (x-axis). FH, familial hypercholesterolaemia; PBMC,
peripheral blood mononuclear cells. Abbreviations of gene names are found in supplemental material.
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Fig. 4 Correlation heatmap of clinical variables and significant genes at FDR < 0.05 within main gene groups from both FH
(n = 30) and healthy children (n = 21). Method is Spearman’s rank correlation. Data are based on a 4-way ANOVA using log2-
transformed data as input,with strip, age and sex as factors. ANOVA, analysis of variance; Apo, apolipoprotein; CRP, C-reactive
protein; FDR, false discovery rate; FH, familial hypercholesterolaemia; HDL-C, high-density lipoprotein cholesterol; IL,
interleukin; LDL-C, low-density lipoprotein cholesterol; oxLDL, oxidized low-density lipoprotein; TLR, toll-like receptor; TNFSF,
tumournecrosis factor super family; total-C, total cholesterol. Abbreviationsof genenamesare found insupplementalmaterial.
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thickening [20]. We observed higher expression of
CTLA4, CTLA4-TM and CD28 in FH children com-
pared to control children; in particular, CTLA4 was
the most significant DEG. Secondly, the ICOS:
ICOSL axis is involved in T-cell proliferation into T
helper 2-cells and is also of major importance for
B- and T-cell interaction [16]. Moreover, ICOS has
been shown to be present in human and murine
atherosclerotic plaques [21, 22] and may be
induced by oxLDL [21]. Expression of ICOS was
higher in FH children compared to control chil-
dren. Thus, our data may suggest an active regu-
lation of T-cell responses mediated by the B7-CD28
superfamily as well as T- and B-cell interaction
mediated by ICOS:ICOSL in children with FH.
Interestingly, CTLA4 in addition to the JAK path-
way were up-regulated in FH children, and impor-
tantly, these pathways can be therapeutically
targeted by medications used in various autoim-
mune disorders [23, 24]. If these pathways are up-
regulated in the early stages of atherosclerosis,
they could potentially represent interesting future
therapeutic targets for prevention of atherosclero-
sis progression.
The intracellular signal transducers of the TNF
receptor-associated factor (TRAF) family regulate
cell survival, proliferation, differentiation and acti-
vation in addition to cytokine production and
autophagy [25]. Pathways activated through
CD40 or BAFFR via TRAF1/2/3/5/6 may subse-
quently activate mitogen-activated protein kinases
or trigger BCL2 transcription, respectively, in B
cells [25]. Regarding prevention of atherosclerosis,
targeting TRAF6 through CD40 has drawn atten-
tion [26], but enhanced expression of TRAF1/2/3/
5 in human atherosclerotic plaques also indicate a
role of these TRAF members in atherosclerosis [27].
We found higher expression of BAFFR
(TNFRSF13C), TRAF1/3/5, MAP4K2 and BCL2 in
children with FH, possibly suggesting LDL-C-in-
duced activation of several TRAF members and
pathways in PBMCs, and again, some of these
could be targeted therapeutically [26].
Previously, we and others have shown increased
systemic inflammation in children with FH, in
particular, an imbalance between TNFSF members
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Fig. 5 Changes in gene expression are similar using either FH status or LDL-C as the exposure variable. The figure shows
the strong association between difference in PBMC gene expression in FH children (n = 30) compared with healthy children
(n = 21) (x-axis) and difference in PBMC gene expression in the same genes per mmol/L difference in LDL-C (all FH and
healthy children, n = 51) (y-axis). Note that the figure shows two regression lines: one solid black reference line
(intercept = 0 and slope = 0.25), and one in dashed blue (specifics highlighted at plot). Note the high similarity between the
reference line and the actual regression line. Interpretation: each grey or orange point represents a combination of two linear
regression estimates; orange-coloured points are the top 20 genes with highest absolute value of residuals (i.e. the 20 points
that deviate the most from the blue linear regression line). R2 for the association is 0.63.
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neopterin [30, 31]. Indeed, using a single-gene
approach, we have previously observed altered
gene expression of certain TNFSF-related genes in
the same children with FH compared to control
children [12]. However, a holistic approach to map
not only single genes but a wide range of candidate
genes is important to expand our understanding of
atherosclerosis and is of clinical relevance in the
prevention of CHD. The present study is to the best
of our knowledge the first study to perform a
comprehensive analysis of immune-related gene
expression in young FH children, representing an
early stage of atherosclerosis without any overt
symptoms, compared to healthy children, con-
tributing to characterize the early inflammatory
profile in this disorder.
Our multivariate analyses suggest that LDL-C is
the main driver of the different expression of
immune-related genes in FH children compared
to control children. Indeed, ten genes were reduced
and three were increased after statin initiation,
indicating normalization towards the expression
level in healthy controls. This further supports a
crucial impact of LDL-C on these immune genes. In
line with others, we have, in the same FH children,
shown changes in inflammatory molecules at gene
expression and circulating level after statins [12,
30] or apheresis [32] in children with FH. In
contrast, we have previously shown a lasting
presence of low-grade inflammation in adults with
FH despite long-term LLT [33], which questions
whether statins or other LLT completely can
reverse the detrimental effects of elevated LDL-C
on the immune system for many years in child-
hood. Nonetheless, our findings further support a
role for LDL-C as a trigger of inflammation and
show that statins could modulate several pathways
that are dysregulated in PBMC from FH children.
Most data suggest that the anti-inflammatory effect
of statins is mediated through the lipid-lowering
effect [34–36]; however, anti-inflammatory effects
of statins cannot be ruled out. Hence, if these
effects in FH children are secondary to down-
regulation of LDL-C, direct immunomodulatory
effects or a combination thereof is at present not
clear.
The major strength of this study is the comprehen-
sive analysis of about 600 immune-related mRNA
molecules in PBMCs by using state-of-the-art
Nanostring technology, and subsequent statistical
and bioinformatic analyses. Secondly, genetically
verified FH children unbiased by LLT are suitable
for studying the pathophysiological role of isolated,
elevated levels of LDL-C. The main limitations are
the relatively low number of subjects, which
increases the probability of type 1 and 2 errors,
and lack of measurement of subclinical atheroscle-
rosis, for example IMT. Furthermore, a previous
study has shown that neither leucocyte, lympho-
cyte nor monocyte count did differ between FH
subjects and healthy controls [37]; however, we
have recently shown altered distribution of leuco-
cytes in FH children [11]. Moreover, our CIBER-
SORT analysis shows a slightly different
distribution in some predicted subtypes; thus,
another limitation is the lack of leucocyte count
as we cannot account for confounding association
with leucocyte subset. Since PBMCs are exposed to
atherogenic factors and are pivotal in the
atherosclerotic process, we have used these cells
as a model system to investigate inflammation in
atherosclerosis. However, this model does not
necessarily reflect the in vivo situation and other
methods could have been used, such as macro-
phage stimulation in vitro.
In conclusion, FH children display higher PBMC
expression of immune-related genes mapped to
several pathways, including T and B cells, TNFSF
and cell growth, proliferation and differentiation
than healthy children. These novel data support
the notion that several immune cells and related
pathways play a role in the early stage of
atherosclerosis before any disease manifestation.
Our results suggest that LDL-C plays a key role in
modulating expression of different immune-related
genes. Some of the genes that were characterized in
PBMC from FH children could potentially also
represent future therapeutic targets for prevention
of atherosclerosis progression.
Acknowledgement
We gratefully thank all the children and young
adults participating in this study. We also thank
the Department of Medical Biochemistry at Oslo
University Hospital, Rikshospitalet, for excellent
technical assistance.
Financial support
This work was supported by the University of Oslo,
Norway, the Norwegian National Advisory Unit on
FH, Oslo University Hospital, Oslo, Norway, the
Throne-Holst Foundation for Nutrition Research,
Oslo, Norway and the South-Eastern Regional
Gene expression in FH children / I. Narverud et al.
10 ª 2019 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication
Journal of Internal Medicine
Health Authority, Oslo, Norway and the Research
Council of Norway through its Centres of Excel-
lence [grant number #223255/F50].
Conflict of interest statement
Dr. Ulven has received research grants and/or
personal fees from Mills DA, Tine BA and Rimfrost,
none of which are related to the content of this
manuscript. Dr. Bogsrud has received research
grants and/or personal fees from Amgen, Sanofi,
MSD, Boehringer Ingelheim, Mills DA and Kaneka,
none of which are related to the content of this
manuscript. Dr. Retterstøl has received research
grants and/or personal fees from Amgen, Mills DA,
The Directorate for Health in Norway, The Norwe-
gian Medical Association, Sanofi, Chiesi, Takeda,
Bayer and MSD, none of which are related to the
content of this manuscript. Dr. Holven reports
grants and/or personal fees from Tine SA, Mills
DA, Olympic Seafood, Amgen, Sanofi, Kaneka and
Pronova, none of which are related to the content of
this manuscript. The other authors have no finan-
cial relationships relevant to disclose.
Authors’ contribution
Authors’ contribution: IN, JJC, SSB, BH and K.B.H.
conceived and designed research; I.N., J.J.C.,
S.S.B., A.R. and K.B.H. conducted research; I.N.,
J.J.C., S.S.B. and A.R. performed statistical analy-
ses; I.N., J.J.C., S.S.B., S.M.U., A.R., P.A., T.E.,
M.P.B., K.R., T.U., B.H. and K.B.H. interpreted
results; I.N., J.J.C. and K.B.H were responsible for
drafting the manuscript; I.N., J.J.C. and K.B.H.
were responsible for final content; all authors read,
critically revisedandapproved thefinalmanuscript.
References
1 Piepoli MF, Hoes AW, Agewall S et al. 2016 European
Guidelines on cardiovascular disease prevention in clinical
practice: The Sixth Joint Task Force of the European Society
of Cardiology and Other Societies on Cardiovascular Disease
Prevention in Clinical Practice (constituted by representatives
of 10 societies and by invited experts) Developed with the
special contribution of the European Association for Cardio-
vascular Prevention & Rehabilitation (EACPR). Eur Heart J
2016; 37: 2315–81.
2 Libby P, Loscalzo J, Ridker PM et al. Inflammation, Immunity,
and Infection in Atherothrombosis: JACC Review Topic of the
Week. J Am Coll Cardiol 2018; 72: 2071–81.
3 Afman L, Milenkovic D, Roche HM. Nutritional aspects of
metabolic inflammation in relation to health–insights from
transcriptomic biomarkers in PBMC of fatty acids and
polyphenols. Mol Nutr Food Res 2014; 58: 1708–20.
4 Visvikis-Siest S, Marteau JB, Samara A, Berrahmoune H,
Marie B, Pfister M. Peripheral blood mononuclear cells
(PBMCs): a possible model for studying cardiovascular biology
systems. Clin Chem Lab Med 2007; 45: 1154–68.
5 Gregersen I, Sandanger O, Askevold ET et al. Interleukin
27 is increased in carotid atherosclerosis and promotes
NLRP3 inflammasome activation. PLoS ONE 2017; 12:
e0188387.
6 Paramel Varghese G, Folkersen L, Strawbridge RJ et al.
NLRP3 Inflammasome Expression and Activation in Human
Atherosclerosis. J Am Heart Assoc 2016; 5.
7 Olofsson PS, Soderstrom LA, Wagsater D et al. CD137 is
expressed in human atherosclerosis and promotes develop-
ment of plaque inflammation in hypercholesterolemic mice.
Circulation 2008; 117: 1292–301.
8 Mata P, Alonso R. Perez de Isla L. Atherosclerotic cardiovas-
cular disease risk assessment in familial hypercholes-
terolemia: does one size fit all? Curr Opin Lipidol 2018; 29:
445–52.
9 Vallejo-Vaz AJ, Kondapally Seshasai SR, Cole D et al. Familial
hypercholesterolaemia: A global call to arms. Atherosclerosis
2015; 243: 257–9.
10 Narverud I, Retterstol K, Iversen PO et al. Markers of
atherosclerotic development in children with familial hyper-
cholesterolemia: A literature review. Atherosclerosis 2014;
235: 299–309.
11 Christensen JJ, Osnes LT, Halvorsen B et al. Altered leuko-
cyte distribution under hypercholesterolemia: A cross-sec-
tional study in children with familial hypercholesterolemia.
Atherosclerosis 2017; 256: 67–74.
12 Narverud I, Halvorsen B, Nenseter MS et al. Oxidized LDL
level is related to gene expression of tumour necrosis factor
super family members in children and young adults with
familial hypercholesterolaemia. J Intern Med 2013; 273: 69–
78.
13 R Core Team. R A Language and Environment for Statistical
Computing. Vienna, Austria: R Foundation for Statistical
Computing, 2018.
14 Newman AM, Liu CL, Green MR et al. Robust enumeration of
cell subsets from tissue expression profiles. Nat Methods
2015; 12: 453–7.
15 Gistera A, Ketelhuth DFJ. Lipid-driven immunometabolic
responses in atherosclerosis. Curr Opin Lipidol 2018; 29:
375–80.
16 Gerdes N, Zirlik A. Co-stimulatory molecules in and beyond
co-stimulation - tipping the balance in atherosclerosis?
Thromb Haemost 2011; 106: 804–13.
17 Collins M, Ling V, Carreno BM. The B7 family of immune-
regulatory ligands. Genome Biol 2005; 6: 223.
18 Lee TS, Yen HC, Pan CC, Chau LY. The role of interleukin 12
in the development of atherosclerosis in ApoE-deficient mice.
Arterioscler Thromb Vasc Biol 1999; 19: 734–42.
19 Buono C, Pang H, Uchida Y, Libby P, Sharpe AH, Lichtman
AH. B7–1/B7-2 costimulation regulates plaque antigen-
specific T-cell responses and atherogenesis in low-density
lipoprotein receptor-deficient mice. Circulation 2004; 109:
2009–15.
20 Yan S, Zhang Q, Cai M et al. A novel model of portal vein
transplantation in mice using two-cuff technique. Micro-
surgery 2007; 27: 569–74.
Gene expression in FH children / I. Narverud et al.
ª 2019 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication 11
Journal of Internal Medicine
21 Afek A, Harats D, Roth A, Keren G, George J. A functional role
for inducible costimulator (ICOS) in atherosclerosis.
Atherosclerosis 2005; 183: 57–63.
22 Niinisalo P, Oksala N, Levula M et al. Activation of indolea-
mine 2,3-dioxygenase-induced tryptophan degradation in
advanced atherosclerotic plaques: Tampere vascular study.
Ann Med 2010; 42: 55–63.
23 Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. JAK-
STAT Signaling as a Target for Inflammatory and Autoim-
mune Diseases: Current and Future Prospects. Drugs 2017;
77: 521–46.
24 Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving
target in immunotherapy. Blood 2018; 131: 58–67.
25 Xie P. TRAF molecules in cell signaling and in human
diseases. J Mol Signal 2013; 8: 7.
26 Seijkens TTP, van Tiel CM, Kusters PJH et al. Targeting
CD40-Induced TRAF6 Signaling in Macrophages Reduces
Atherosclerosis. J Am Coll Cardiol 2018; 71: 527–42.
27 Zirlik A, Bavendiek U, Libby P et al. TRAF-1, -2, -3, -5, and -6
are induced in atherosclerotic plaques and differentially
mediate proinflammatory functions of CD40L in endothelial
cells. Arterioscler Thromb Vasc Biol 2007; 27: 1101–7.
28 Narverud I, Ueland T, Nenseter MS et al. Children with familial
hypercholesterolemia are characterized by an inflammatory
imbalancebetween the tumornecrosis factor alpha systemand
interleukin-10. Atherosclerosis 2011; 214: 163–8.
29 Guardamagna O, Abello F, Saracco P, Baracco V, Rolfo E,
Pirro M. Endothelial activation, inflammation and premature
atherosclerosis in children with familial dyslipidemia.
Atherosclerosis 2009; 207: 471–5.
30 Ueland T, Vissers MN, Wiegman A et al. Increased inflamma-
tory markers in children with familial hypercholesterolaemia.
Eur J Clin Invest 2006; 36: 147–52.
31 Holven KB, Damas JK, Yndestad A et al. Chemokines in
children with heterozygous familiar hypercholesterolemia:
selective upregulation of RANTES. Arterioscler Thromb Vasc
Biol 2006; 26: 200–5.
32 Kucukcongar A, Yenicesu I, Tumer L et al. Apheresis-
inducible cytokine pattern change in children with homozy-
gous familial hypercholesterolemia. Transfus Apher Sci 2013;
48: 391–6.
33 Holven KB, Narverud I, Lindvig HW et al. Subjects with
familial hypercholesterolemia are characterized by an inflam-
matory phenotype despite long-term intensive cholesterol
lowering treatment. Atherosclerosis 2014; 233: 561–7.
34 Rezaie-Majd A, Maca T, Bucek RA et al. Simvastatin reduces
expression of cytokines interleukin-6, interleukin-8, and
monocyte chemoattractant protein-1 in circulating mono-
cytes from hypercholesterolemic patients. Arte-
riosclerThrombVascBiol 2002; 22: 1194–9.
35 Bahrami A, Parsamanesh N, Atkin SL, Banach M, Sahebkar
A. Effect of statins on toll-like receptors: a new insight to
pleiotropic effects. Pharmacol Res 2018; 135: 230–8.
36 Arnaud C, Burger F, Steffens S et al. Statins reduce inter-
leukin-6-induced C-reactive protein in human hepatocytes:
new evidence for direct antiinflammatory effects of statins.
Arterioscler Thromb Vasc Biol 2005; 25: 1231–6.
37 Bernelot Moens SJ, Neele AE, Kroon J et al. PCSK9 mono-
clonal antibodies reverse the pro-inflammatory profile of
monocytes in familial hypercholesterolaemia. Eur Heart J
2017; 38: 1584–93.
Correspondence: Ingunn Narverud, Department of Nutrition,
Institute of basic medical sciences, University of Oslo, P.O box
1046 Blindern, 0317 Oslo, Norway.
(fax: +47 22851341; e-mail: Ingunn.narverud@medisin.uio.no).
Supporting Information
Additional Supporting Information may be found in
the online version of this article:
Figure S1. Predicted leucocyte subtypes using
CIBERSORT analysis based on all the mRNA
expressions from the nCounter analysis in children
with (n = 30) and without (n = 21) FH.
Figure S2. Differential gene expression before and
after statin initiation in FH children (n = 10) at
P < 0.05.
Figure S3. Association between fold difference and
nominal P-value for all genes in FH (n = 30) and
healthy children (n = 21).
Gene expression in FH children / I. Narverud et al.
12 ª 2019 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication
Journal of Internal Medicine
